Xencor (XNCR) Competitors

$11.88 -0.50 (-4.04%)

Closing price 04:00 PM Eastern

Extended Trading

$11.88 -0.01 (-0.04%)

As of 04:56 PM Eastern

XNCR vs. CPRX, NNNN, ACAD, EWTX, and VKTX

Should you buy Xencor stock or one of its competitors? MarketBeat compares Xencor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xencor include Catalyst Pharmaceuticals (CPRX), Anbio Biotechnology (NNNN), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.

How does Xencor compare to Catalyst Pharmaceuticals?

Xencor (NASDAQ:XNCR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Xencor presently has a consensus target price of $24.50, suggesting a potential upside of 106.23%. Catalyst Pharmaceuticals has a consensus target price of $32.17, suggesting a potential upside of 3.23%. Given Xencor's higher possible upside, research analysts clearly believe Xencor is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Catalyst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	3 Strong Buy rating(s)	2.88

Catalyst Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	9.05	-$91.92M	-$2.29	N/A
Catalyst Pharmaceuticals	$596.96M	6.39	$214.33M	$1.74	17.91

Xencor has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Xencor's net margin of -177.10%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

In the previous week, Catalyst Pharmaceuticals had 6 more articles in the media than Xencor. MarketBeat recorded 17 mentions for Catalyst Pharmaceuticals and 11 mentions for Xencor. Xencor's average media sentiment score of 0.53 beat Catalyst Pharmaceuticals' score of 0.34 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 4.8% of Xencor shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Xencor on 12 of the 17 factors compared between the two stocks.

How does Xencor compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Xencor (NASDAQ:XNCR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Xencor has a consensus price target of $24.50, suggesting a potential upside of 106.23%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anbio Biotechnology has higher earnings, but lower revenue than Xencor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	417.19	$6.40M	N/A	N/A
Xencor	$97.36M	9.05	-$91.92M	-$2.29	N/A

Anbio Biotechnology has a beta of 4.71, suggesting that its stock price is 371% more volatile than the broader market. Comparatively, Xencor has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Anbio Biotechnology's return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, Xencor had 10 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for Xencor and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.19 beat Xencor's score of 0.53 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Xencor	Positive

Summary

Anbio Biotechnology beats Xencor on 7 of the 12 factors compared between the two stocks.

How does Xencor compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

ACADIA Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 40.33%. Xencor has a consensus price target of $24.50, suggesting a potential upside of 106.23%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.75
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

ACADIA Pharmaceuticals has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.10B	3.45	$391M	$2.20	10.04
Xencor	$97.36M	9.05	-$91.92M	-$2.29	N/A

ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Xencor has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Xencor's net margin of -177.10%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, ACADIA Pharmaceuticals had 14 more articles in the media than Xencor. MarketBeat recorded 25 mentions for ACADIA Pharmaceuticals and 11 mentions for Xencor. Xencor's average media sentiment score of 0.53 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xencor	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats Xencor on 13 of the 17 factors compared between the two stocks.

How does Xencor compare to Edgewise Therapeutics?

Xencor (NASDAQ:XNCR) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Xencor currently has a consensus price target of $24.50, suggesting a potential upside of 106.23%. Edgewise Therapeutics has a consensus price target of $39.67, suggesting a potential upside of 16.63%. Given Xencor's higher probable upside, equities analysts plainly believe Xencor is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Xencor had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Xencor and 7 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.95 beat Xencor's score of 0.53 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Xencor has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	9.05	-$91.92M	-$2.29	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Xencor has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Summary

Xencor beats Edgewise Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Xencor compare to Viking Therapeutics?

Xencor (NASDAQ:XNCR) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Xencor currently has a consensus price target of $24.50, suggesting a potential upside of 106.23%. Viking Therapeutics has a consensus price target of $95.50, suggesting a potential upside of 201.17%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85

76.0% of Viking Therapeutics shares are held by institutional investors. 4.8% of Xencor shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Xencor had 6 more articles in the media than Viking Therapeutics. MarketBeat recorded 11 mentions for Xencor and 5 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.28 beat Xencor's score of 0.53 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Viking Therapeutics	N/A	-71.31%	-65.35%

Xencor has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Xencor has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	9.05	-$91.92M	-$2.29	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Summary

Xencor beats Viking Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$880.81M	$3.05B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-5.19	19.11	20.89	25.59
Price / Sales	9.05	280.24	523.74	63.24
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	1.71	4.35	9.86	6.70
Net Income	-$91.92M	$72.19M	$3.55B	$333.77M
7 Day Performance	-3.49%	-0.62%	-0.33%	0.45%
1 Month Performance	-5.04%	0.22%	1.34%	4.06%
1 Year Performance	45.95%	46.24%	41.10%	36.24%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.4095 of 5 stars	$11.88 -4.0%	$24.50 +106.2%	+52.7%	$880.81M	$97.36M	N/A	280	Analyst Forecast
CPRX Catalyst Pharmaceuticals	4.2158 of 5 stars	$31.16 +0.0%	$32.17 +3.2%	+31.8%	$3.81B	$588.99M	18.43	80
NNNN Anbio Biotechnology	0.8945 of 5 stars	$26.38 +4.1%	N/A	N/A	$3.80B	$8.65M	N/A	27	Positive News
ACAD ACADIA Pharmaceuticals	4.3699 of 5 stars	$21.99 +0.9%	$31.00 +41.0%	+29.0%	$3.76B	$1.07B	9.98	510	Analyst Revision
EWTX Edgewise Therapeutics	2.4226 of 5 stars	$34.37 -0.5%	$39.67 +15.4%	+126.7%	$3.69B	N/A	N/A	60	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. CPRX, NNNN, ACAD, EWTX, and VKTX

How does Xencor compare to Catalyst Pharmaceuticals?

Summary

How does Xencor compare to Anbio Biotechnology?

Summary

How does Xencor compare to ACADIA Pharmaceuticals?

Summary

How does Xencor compare to Edgewise Therapeutics?

Summary

How does Xencor compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. CPRX, NNNN, ACAD, EWTX, and VKTX

How does Xencor compare to Catalyst Pharmaceuticals?

Do analysts rate XNCR or CPRX?

Which has preferable valuation & earnings, XNCR or CPRX?

Which has more risk and volatility, XNCR or CPRX?

Is XNCR or CPRX more profitable?

Does the media refer more to XNCR or CPRX?

Do insiders & institutionals hold more shares of XNCR or CPRX?

Summary

How does Xencor compare to Anbio Biotechnology?

Do analysts recommend NNNN or XNCR?

Which has preferable valuation & earnings, NNNN or XNCR?

Which has more risk and volatility, NNNN or XNCR?

Is NNNN or XNCR more profitable?

Does the media prefer NNNN or XNCR?

Summary

How does Xencor compare to ACADIA Pharmaceuticals?

Do analysts recommend ACAD or XNCR?

Which has preferable valuation & earnings, ACAD or XNCR?

Which has more risk & volatility, ACAD or XNCR?

Is ACAD or XNCR more profitable?

Does the media prefer ACAD or XNCR?

Do insiders and institutionals hold more shares of ACAD or XNCR?

Summary

How does Xencor compare to Edgewise Therapeutics?

Do analysts rate XNCR or EWTX?

Does the media prefer XNCR or EWTX?

Is XNCR or EWTX more profitable?

Which has higher earnings and valuation, XNCR or EWTX?

Which has more volatility and risk, XNCR or EWTX?

Summary

How does Xencor compare to Viking Therapeutics?

Do analysts rate XNCR or VKTX?

Do insiders & institutionals believe in XNCR or VKTX?

Does the media refer more to XNCR or VKTX?

Is XNCR or VKTX more profitable?

Which has more volatility and risk, XNCR or VKTX?

Which has better earnings & valuation, XNCR or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools